Cyclerion Therapeutics, Inc.
CYCN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $1 | $0 | $0 | $2 |
| % Growth | 840.9% | 14.8% | -95.5% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $1 | $0 | $0 | $2 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $2 | $2 | $2 | $1 |
| SG&A Expenses | $2 | $2 | $2 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $2 | $2 | $2 | $1 |
| Operating Income | -$1 | -$2 | -$1 | $1 |
| % Margin | -115% | -1,797.8% | -1,798.8% | 27.8% |
| Other Income/Exp. Net | $0 | $1 | $0 | $0 |
| Pre-Tax Income | -$1 | -$0 | -$1 | $1 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$1 | -$0 | -$1 | $1 |
| % Margin | -111.5% | -348.4% | -1,764.2% | 29.3% |
| EPS | -0.3 | -0.11 | -0.56 | 0.21 |
| % Growth | -172.7% | 80.4% | -366.7% | – |
| EPS Diluted | -0.3 | -0.11 | -0.56 | 0.21 |
| Weighted Avg Shares Out | 3 | 3 | 3 | 3 |
| Weighted Avg Shares Out Dil | 3 | 3 | 3 | 3 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$1 | -$2 | -$1 | $1 |
| % Margin | -111.5% | -1,797.8% | -1,798.8% | 27.8% |